BioNTech SE (BNTX) (Q3 2026) Earnings Call Highlights: Oncology Pipeline Momentum Builds as ...

Negative Points

• Total revenues declined to EUR 1.3 billion in Q3 2026 from EUR 1.5 billion in the prior year, mainly due to anticipated lower COVID-19 vaccine demand.

• Adjusted R&D expenses increased to EUR 579 million from EUR 479 million year-over-year, reflecting greater investment in prioritized programs, which may pressure near-term profitability.

• The Phase 2 trial of autogene cevumeran in adjuvant colorectal cancer was discontinued due to a numerical imbalance in overall survival, raising concerns about the mRNA cancer immunotherapy program.

• The Phase 2/3 trial of BNT113 in HPV16-positive head and neck cancer did not meet its primary endpoint of progression-free survival at the first interim analysis, although it continues for overall survival.

• The Phase 3 trial of trastuzumab pamitecan (TPAM) in HER2-low metastatic breast cancer showed only a modest improvement in progression-free survival, with a higher rate of interstitial lung disease, limiting its potential benefit.

Q & A Highlights

Q: How confident is BioNTech in the Gotistobart (oncology asset) interim analyses, and which one should investors focus on? A: Chief Medical Officer Ozlem Tureci said the team is very excited about Gotistobart, noting the near doubling of median overall survival seen in the non-pivotal part of the Phase 3 trial. The first interim analysis is expected before year-end 2026, with a second preplanned interim in 2027. She cautioned that the first interim is early, so a lack of a clear signal at that point would not be disappointing.

Q: What is the rationale behind changing the economics of the Roche/Genentech mRNA collaboration, and does it signal reduced commitment to cancer vaccines? A: CEO Ugur Sahin said the change is mainly a resource allocation decision that gives BioNTech flexibility to fund other priority pipeline programs, and should not be read as a lack of commitment to mRNA. CFO Ramon Zapata added that BioNTech exercised a contractual option under which, from January 1, future R&D costs for the program shift to Roche/Genentech, moving from a 50-50 cost/profit share to royalty-based economics, while BioNTech retains royalty upside and transitional supply responsibilities for the PDAC program.

Q: What were the key Pumitamig plus LPD (B7-H3 ADC) combination data in small cell lung cancer, and what are the next steps? A: Tureci highlighted a 92% overall response rate in first-line, 76% in second-line and 52% in third-line or later small cell lung cancer, with a 2.9% ILD rate and no dose-limiting toxicities. She said the data support Pumitamig as a potential backbone for chemotherapy-free regimens, but specific indications, settings and timing for pivotal trials have not yet been decided and will be disclosed as part of 2027 milestones.

Q: What is the status of the TROP2 ADC and how is BioNTech thinking about Pumitamig combinations beyond triple-negative breast cancer? A: Tureci said BioNTech has signal-seeking trials combining all of its ADCs, including the TROP2 ADC, with Pumitamig, and is assessing the different ADCs by target rather than through a single-ADC lens to determine which combinations to advance in which indications. A company representative added that Pumitamig is viewed as a backbone across settings and tumor types, with focus on lung, breast, GI and GU cancers, and that combinations are being pursued with BioNTech's own portfolio, BMS and external partners such as Gilead.

Q: What is the regulatory path forward for the TPAM HER2 ADC following the Phase 3 breast cancer results? A: Tureci said BioNTech has not yet held detailed discussions with regulators on TPAM. The company has an understanding of the potential path forward and will refine it based on the totality of data from Part 2 of the trial before engaging regulators. A company representative added that BioNTech and Duality Bio are discussing the totality of clinical data across endometrial and breast cancer, including a potential BLA submission, and will update the market accordingly.

Q: Is there read-through from the discontinued colorectal cancer mRNA trial to the PDAC program? A: Tureci said the two are different questions and different experiments. While both are "cold" tumors with relatively low mutational burden, they have entirely different tumor biologies and different vaccine positioning: the colorectal trial used the vaccine as monotherapy, whereas the PDAC trial integrates it into chemotherapy and combines it with checkpoint inhibition.

Q: How should investors think about the read-through from the Summit HARMONi-3 trial to BioNTech's ROSETTA Lung 2 trial? A: Tureci said BioNTech will pay attention to HARMONi-3, which shares the same patient population and comparator as ROSETTA Lung 2, but the two studies differ in endpoints, sample size assumptions, trial architecture, stratification methods and site/country mix. She said there is no clear read-through mechanism from HARMONi-3 to ROSETTA Lung 2, and BioNTech will stay committed to its studies regardless, noting that Phase 2 data in this population have been very encouraging.

Q: What are the enrollment progress and expected timing for the Pumitamig Phase 3 readouts? A: Tureci said BioNTech will have seven global pivotal studies ongoing by the end of 2026, all event-driven, so exact sequencing and timing cannot be predicted with confidence. Based on current primary completion dates on clinicaltrials.gov, the first readout is expected in first-line TNBC in China, followed by ROSETTA Lung around 2029, then RCC, CRC, HCC and others, though timing may shift as studies mature.

Q: Will BioNTech comment on the Gotistobart first interim analysis outcome once it occurs, and what is the commercial opportunity? A: A company representative said BioNTech would comment one way or the other once the IDMC reviews the first interim analysis, including if the committee recommends the study continue. On commercial potential, the representative estimated around 55,000 second-line squamous non-small cell lung cancer patients in the G7 by 2030, a setting with little innovation for a long time, and views Gotistobart as a key asset for building BioNTech into a multiproduct company.

Q: What is the latest on the cancer vaccine strategy, including tumor types and settings, under the incoming management team? A: Sahin said it is premature to discuss new management priorities, but the current strategy includes continuing to advance the BNT113 and BNT116 programs and early-stage mRNA platform efforts. On combining with chemotherapy, Tureci said the choice depends on the standard of care and backbone in each indication, and that recent data show combining with chemo is feasible and can improve effect by supporting antigen spreading, as reflected in the PDAC and BNT116 studies.

Q: What is the financial outlook for 2027? A: CFO Ramon Zapata said it is premature to discuss 2027 guidance. BioNTech is currently working on its plans and will update the market at a later stage.

For the complete transcript of the earnings call, please refer to the full earnings call transcript .